These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 27659159)

  • 1. Optimizing Clinical Drug Product Performance: Applying Biopharmaceutics Risk Assessment Roadmap (BioRAM) and the BioRAM Scoring Grid.
    Dickinson PA; Kesisoglou F; Flanagan T; Martinez MN; Mistry HB; Crison JR; Polli JE; Cruañes MT; Serajuddin ATM; Müllertz A; Cook JA; Selen A
    J Pharm Sci; 2016 Nov; 105(11):3243-3255. PubMed ID: 27659159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The biopharmaceutics risk assessment roadmap for optimizing clinical drug product performance.
    Selen A; Dickinson PA; Müllertz A; Crison JR; Mistry HB; Cruañes MT; Martinez MN; Lennernäs H; Wigal TL; Swinney DC; Polli JE; Serajuddin ATM; Cook JA; Dressman JB
    J Pharm Sci; 2014 Nov; 103(11):3377-3397. PubMed ID: 25256402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated Multi-stakeholder Systems Thinking Strategy: Decision-making with Biopharmaceutics Risk Assessment Roadmap (BioRAM) to Optimize Clinical Performance of Drug Products.
    Selen A; Müllertz A; Kesisoglou F; Ho RJY; Cook JA; Dickinson PA; Flanagan T
    AAPS J; 2020 Jul; 22(5):97. PubMed ID: 32719954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new roadmap for biopharmaceutical drug product development: Integrating development, validation, and quality by design.
    Martin-Moe S; Lim FJ; Wong RL; Sreedhara A; Sundaram J; Sane SU
    J Pharm Sci; 2011 Aug; 100(8):3031-3043. PubMed ID: 21425164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrating biopharmaceutics risk assessment and in vivo absorption model in formulation development of BCS class I drug using the QbD approach.
    Charoo NA; Cristofoletti R; Kim SK
    Drug Dev Ind Pharm; 2017 Apr; 43(4):668-677. PubMed ID: 28032517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correction to: Integrated Multi-stakeholder Systems Thinking Strategy: Decision-making with Biopharmaceutics Risk Assessment Roadmap (BioRAM) to Optimize Clinical Performance of Drug Products.
    Selen A; Müllertz A; Kesisoglou F; Ho RJY; Cook JA; Dickinson PA; Flanagan T
    AAPS J; 2020 Dec; 23(1):7. PubMed ID: 33270171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.
    Lennernäs H; Aarons L; Augustijns P; Beato S; Bolger M; Box K; Brewster M; Butler J; Dressman J; Holm R; Julia Frank K; Kendall R; Langguth P; Sydor J; Lindahl A; McAllister M; Muenster U; Müllertz A; Ojala K; Pepin X; Reppas C; Rostami-Hodjegan A; Verwei M; Weitschies W; Wilson C; Karlsson C; Abrahamsson B
    Eur J Pharm Sci; 2014 Jun; 57():292-9. PubMed ID: 24189462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scientific and Regulatory Considerations in Solid Oral Modified Release Drug Product Development.
    Li M; Sander S; Duan J; Rosencrance S; Miksinski SP; Yu L; Seo P; Rege B
    AAPS J; 2016 Nov; 18(6):1406-1417. PubMed ID: 27650190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment Methodology for Process Validation Lifecycle Stage 3A.
    Sayeed-Desta N; Pazhayattil AB; Collins J; Chen S; Ingram M; Spes J
    AAPS PharmSciTech; 2017 Jul; 18(5):1881-1886. PubMed ID: 27714700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative Bioavailability Risk Assessment: A Systematic Approach to Assessing In Vivo Risk Associated With CM&C-Related Changes.
    Aburub A; Sperry DC; Bhattachar S; Lobo E; Ding X; Rose JP
    J Pharm Sci; 2019 Jan; 108(1):8-17. PubMed ID: 30053554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro - in vivo correlation: from theory to applications.
    Emami J
    J Pharm Pharm Sci; 2006; 9(2):169-89. PubMed ID: 16959187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variability in Flow-Imaging Microscopy Measurements and Considerations for Biopharmaceutical Development.
    Rauk AP; Griffiths KL; Gossage MD; Weiss WF
    J Pharm Sci; 2016 Nov; 105(11):3296-3303. PubMed ID: 27663382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Commonality between BCS and TCS.
    Shah VP; Rădulescu FŞ; Miron DS; Yacobi A
    Int J Pharm; 2016 Jul; 509(1-2):35-40. PubMed ID: 27208656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regional intestinal drug permeation: biopharmaceutics and drug development.
    Lennernäs H
    Eur J Pharm Sci; 2014 Jun; 57():333-41. PubMed ID: 23988845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of in vitro biopharmaceutical methods in development of immediate release oral dosage forms intended for paediatric patients.
    Batchelor HK; Kendall R; Desset-Brethes S; Alex R; Ernest TB;
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):833-42. PubMed ID: 23665448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of determination of biopharmaceutical properties for development candidate selection.
    Yazdanian M
    Curr Protoc Pharmacol; 2013 Mar; Chapter 9():Unit9.17. PubMed ID: 23456615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Six years of progress in the oral biopharmaceutics area - A summary from the IMI OrBiTo project.
    Abrahamsson B; McAllister M; Augustijns P; Zane P; Butler J; Holm R; Langguth P; Lindahl A; Müllertz A; Pepin X; Rostami-Hodjegan A; Sjögren E; Berntsson M; Lennernäs H
    Eur J Pharm Biopharm; 2020 Jul; 152():236-247. PubMed ID: 32446960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The developability classification system: application of biopharmaceutics concepts to formulation development.
    Butler JM; Dressman JB
    J Pharm Sci; 2010 Dec; 99(12):4940-54. PubMed ID: 20821390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An updated overview with simple and practical approach for developing in vitro-in vivo correlation.
    Jacob S; Nair AB
    Drug Dev Res; 2018 May; 79(3):97-110. PubMed ID: 29697151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. QbD-Enabled Development of Novel Stimuli-Responsive Gastroretentive Systems of Acyclovir for Improved Patient Compliance and Biopharmaceutical Performance.
    Singh B; Kaur A; Dhiman S; Garg B; Khurana RK; Beg S
    AAPS PharmSciTech; 2016 Apr; 17(2):454-65. PubMed ID: 26238805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.